ONESOURCE SPECL PHARMA L Q2 Results FY27: PAT Jumps 447.95% to Rs 57.48 Cr, Revenue Rs 516.24 Cr

ONESOURCE SPECL PHARMA L (ONESOURCE) Q2 Results FY27 announced on 27 October 2026, covering the company's financial performance for the July to September quarter. The results date brought Consolidated revenue of Rs 516.24 Cr and PAT of Rs 57.48 Cr, while ONESOURCE SPECL PHARMA L Q2 Results FY27 also show Operating Profit of Rs 163.29 Cr. These consolidated results compare the quarter with the same period of last year.

This results analysis of ONESOURCE SPECL PHARMA L Q2 Results starts with the Financial Highlights table and then covers the key takeaways, business drivers, outlook and risks. Univest readers can use the figures below to place the quarter against the same quarter of the previous year, beginning with the table that sets revenue, Operating Profit and net profit side by side.

Click Here – Get Free Investment Predictions

ONESOURCE SPECL PHARMA L Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 516.24 Cr	Rs 375.76 Cr	+37.39% YoY
Operating Profit	Rs 163.29 Cr	Rs 106.5 Cr	+53.32% YoY
Net Profit (PAT)	Rs 57.48 Cr	Rs 10.49 Cr	+447.95% YoY

Source: company filing for ONESOURCE SPECL PHARMA L Q2 Results FY27, 27 October 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from ONESOURCE SPECL PHARMA L Q2 Results: What Stands Out

• Revenue: Consolidated revenue rose 37.39% YoY to Rs 516.24 Cr from Rs 375.76 Cr, which is clear YoY growth in the top line.
• Net profit: PAT climbed 447.95% to Rs 57.48 Cr from Rs 10.49 Cr, the sharpest move among the three lines in ONESOURCE SPECL PHARMA L Q2 Results FY27.
• Operating Profit: Operating Profit increased 53.32% to Rs 163.29 Cr from Rs 106.50 Cr in the same quarter of last year.
• Margin: Net profit margin improved to 11.1% from 2.8% in the comparison quarter, based on the figures reported for the quarter.
• Risk headline: Return on equity was low at -1.26% in FY26, a point the performance analysis weighs against the quarterly gains.

ONESOURCE SPECL PHARMA L Q2 Results FY27: Performance Analysis

The numbers show higher figures on all three reported lines. Revenue reached Rs 516.24 Cr, Operating Profit reached Rs 163.29 Cr and net profit reached Rs 57.48 Cr, each above the July to September 2025 quarter, which is the YoY growth that the Financial Highlights table confirms line by line.

Revenue added Rs 140.48 Cr over the year, and Operating Profit added Rs 56.79 Cr. The ONESOURCE SPECL PHARMA L Q2 Results FY27 consolidated figures also show net profit adding Rs 46.99 Cr, so the profit lines grew faster than revenue in percentage terms, with Operating Profit up 53.32% against revenue up 37.39%.

The size of the net profit move comes from a small comparison base of Rs 10.49 Cr, and ONESOURCE SPECL PHARMA L Q2 Results should be read with that base in mind. The Univest Screener lets readers track later disclosures, which is where the results analysis turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth of 37.4% – The results analysis points first to the top line: revenue grew 37.4% year on year to Rs 516.24 Cr in the latest quarter, and this figure sits underneath every other line of the ONESOURCE SPECL PHARMA L Q2 Results FY27 statement.

Net Profit Rising 448.0% – Net profit rose 448.0% year on year to Rs 57.48 Cr, up from Rs 10.49 Cr in the comparison quarter. The reported figures confirm the size of the move but do not establish its specific cause, so this section stays with the numbers.

Net Profit Margin of 11.1% – Net profit margin improved to 11.1% from 2.8% in the comparison quarter. The reported figures show net profit forming a larger share of revenue than it did a year earlier, as the quarterly results table indicates.

FY27 Outlook After ONESOURCE SPECL PHARMA L Q2 Results

Full-year FY27 results will depend on how the coming quarters compare with this one and on disclosed sector conditions. This results analysis therefore treats the latest net profit of Rs 57.48 Cr as one data point in a sequence, and the next filings will add to it.

ONESOURCE SPECL PHARMA L Q2 Results FY27 sit alongside a five-quarter net profit range running from Rs -88.70 Cr to Rs 57.48 Cr, so later disclosures will show whether the present level is repeated. Investors can follow those filings on the Univest app, and the question of consistency leads directly into the risks.

Key Risks to Watch After ONESOURCE SPECL PHARMA L Q2 Results FY27

Low Return on Equity

Return on equity was low at -1.26% in FY26. Against this, the 447.95% YoY growth in net profit starts from a small base of Rs 10.49 Cr, so the full-year return ratios remain a point to check as later quarters arrive.

Modest Return on Capital Employed

Return on capital employed was modest at 0.44% in FY26. That is a full-year measure, and it sits apart from the single-quarter figures reported on 27 October 2026, so the two should be read together and not mixed.

Volatile Quarterly Net Profit

Quarterly net profit has been volatile, ranging from Rs -88.70 Cr to Rs 57.48 Cr over the last 5 quarters. After ONESOURCE SPECL PHARMA L Q2 Results FY27, one strong quarter needs to be read alongside the quarters around it, which brings the discussion to the conclusion.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

ONESOURCE SPECL PHARMA L Q2 Results FY27 record Consolidated revenue of Rs 516.24 Cr and net profit of Rs 57.48 Cr in the quarterly results declared on 27 October 2026. Revenue, Operating Profit and net profit are all higher YoY, while the FY26 return ratios and the volatile net profit history remain on record. The consolidated results in ONESOURCE SPECL PHARMA L Q2 Results therefore need context from later quarters. Investors should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on ONESOURCE SPECL PHARMA L Q2 Results FY27

What are ONESOURCE SPECL PHARMA L Q2 Results FY27?

Ans. ONESOURCE SPECL PHARMA L Q2 Results FY27 are the Consolidated quarterly results for July to September 2026, with revenue of Rs 516.24 Cr, so the Financial Highlights table carries the headline numbers.

What is the results date for ONESOURCE SPECL PHARMA L Q2 Results FY27?

Ans. The results date for ONESOURCE SPECL PHARMA L Q2 Results FY27 is 27 October 2026, covering the July to September 2026 quarter, so the intro and Quick Answer box state the same date.

What revenue was reported in ONESOURCE SPECL PHARMA L Q2 Results FY27?

Ans. ONESOURCE SPECL PHARMA L reported Consolidated revenue of Rs 516.24 Cr, compared with Rs 375.76 Cr a year earlier, which means the top line is shown in the Financial Highlights table.

What net profit was reported in ONESOURCE SPECL PHARMA L Q2 Results FY27?

Ans. ONESOURCE SPECL PHARMA L reported net profit of Rs 57.48 Cr, compared with Rs 10.49 Cr in the same quarter of last year, as the Key Takeaways section lists among the standout figures.

How much YoY growth did revenue show in ONESOURCE SPECL PHARMA L Q2 Results FY27?

Ans. Revenue showed YoY growth of 37.39% for ONESOURCE SPECL PHARMA L, rising from Rs 375.76 Cr to Rs 516.24 Cr, while the Performance Analysis section explains the Rs 140.48 Cr increase in more detail.

Did net profit rise or fall in ONESOURCE SPECL PHARMA L Q2 Results?

Ans. ONESOURCE SPECL PHARMA L Q2 Results show net profit rising 447.95% YoY to Rs 57.48 Cr, so the profit line is higher than a year earlier, and the Key Business Factors section repeats this movement.

What was the Operating Profit in ONESOURCE SPECL PHARMA L Q2 Results FY27?

Ans. Operating Profit for ONESOURCE SPECL PHARMA L was Rs 163.29 Cr, up 53.32% YoY from Rs 106.50 Cr, which means this middle profit line grew alongside revenue, as the Performance Analysis section shows.

Are ONESOURCE SPECL PHARMA L Q2 Results consolidated results or standalone results?

Ans. ONESOURCE SPECL PHARMA L Q2 Results are consolidated results, as the filing was reported on a Consolidated basis, which means the figures cover the group, and the intro paragraphs state this basis directly.

What business factors shaped ONESOURCE SPECL PHARMA L Q2 Results FY27?

Ans. The reported factors for ONESOURCE SPECL PHARMA L are 37.4% revenue growth, a 448.0% rise in net profit and a net profit margin of 11.1% against 2.8%, as the Key Business Factors section sets out.

What are the key risks after ONESOURCE SPECL PHARMA L Q2 Results FY27?

Ans. The risks after ONESOURCE SPECL PHARMA L are return on equity of -1.26% in FY26, return on capital employed of 0.44% and volatile quarterly net profit, which the Key Risks section covers in turn.

What is the outlook after ONESOURCE SPECL PHARMA L Q2 Results?

Ans. Full-year FY27 results will depend on later quarters, so the latest net profit of Rs 57.48 Cr is one data point, and the Outlook section lists what the next filings will add.

Where can I find the complete ONESOURCE SPECL PHARMA L Q2 Results FY27 data?

Ans. The complete figures sit in the Financial Highlights table above, which sets revenue, Operating Profit and net profit against the same quarter last year, and the Univest Screener tracks later filings for ONESOURCE SPECL PHARMA L.